-The Indian Express The United States will pursue negotiations at WTO to waive intellectual property for COVID-19 vaccines. This can allow large-scale production in middle-income countries, but there are arguments against the move. The United States on Wednesday announced support for waiving intellectual property protection for COVID-19 vaccines, saying extraordinary circumstances call for extraordinary measures. United States Trade Representative Katherine Tai said the US will pursue “text-based negotiations” on the waiver at...

-The Hindu The relaxation has been granted for payments received in cash between April 1 and May 31, provided such healthcare providers obtain the PAN or Aadhaar of the patient and the payee. The government has notified changes to the Income Tax Act to allow cash payments of over ₹2 lakh for COVID-19 patients’ treatment at hospitals, dispensaries, nursing homes, COVID care centres or other similar medical facilities. The relaxation has been granted...

-The Hindu Ministry concedes Q1 growth to be hit, bats for expanding vaccination pace. The second COVID-19 wave which is spreading fast beyond the worst-affected districts in the country, could dent economic activity till June this year, and expanding vaccination pace in the country is the “need of the hour”, the Finance Ministry said on Friday. The Ministry also indicated it is not in favour of a national lockdown to curb the pandemic,...

-The Hindu Current price negotiated through bulk orders may not be replicable: Finance Secy The first lot of vaccines were procured by the Centre using PM CARES funds at a higher rate than the subsequent rounds paid for by budgetary allocations, The Hindu has learnt from the response to a Right to Information request by a transparency activist. The Health Ministry response said that the initial 5.6 crore doses of Covishield were bought...

-The Hindu Business Line It’s only an open-ended deal with co-developer Bharat Biotech, says top source The Indian Council of Medical Research (ICMR) is willing to share the know-how to produce the indigenously-developed COVID-19 vaccine, Covaxin, with any company as the contract with co-developer Bharat Biotech is not close-ended. Currently, Bharat Biotech has the sole licence to manufacture Covaxin, which it developed in collaboration with scientists from ICMR’s Pune-based National Institute of Virology...